Long-Term Risk of Major Bleeding after Discontinuing Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis
- 9 November 2021
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 122 (07) , 1186-1197
Abstract
Background The long-term risk of major bleeding after discontinuing anticoagulant therapy for a first unprovoked venous thromboembolism (VTE) is uncertain. Objectives To determine the incidence of major bleeding up to 5 years after discontinuing anticoagulation for a first unprovoked VTE. Methods We searched MEDLINE, EMBASE, and Cochrane CENTRAL (from inception to January 2021) to identify relevant randomized controlled trials (RCTs) and prospective cohort studies reporting major bleeding after discontinuing anticoagulation in patients with a first unprovoked or weakly provoked VTE who had completed (IMAGE_)3 months of initial treatment. Unpublished data on major bleeding events and person-years were obtained from authors of included studies to calculate study-level incidence rates. Random-effects meta-analysis was used to pool results across studies. Results Of 1,123 records identified by the search, 20 studies (17 RCTs) and 8,740 patients were included in the analysis. During 13,011 person-years of follow-up after discontinuing anticoagulation, the pooled incidence of major bleeding (n = 41) and fatal bleeding (n = 7) per 100 person-years was 0.35 (95% confidence interval [CI]: 0.20–0.54) and 0.09 (95% CI: 0.05–0.15). The 5-year cumulative incidence of major bleeding was of 1.0% (95% CI: 0.4–2.4%). The case-fatality rate of major bleeding after discontinuing anticoagulation was 19.9% (95% CI: 10.6–31.1%). Conclusion The risk of major bleeding once anticoagulants are discontinued in patients with a first unprovoked VTE is not zero. Estimates from this study can help clinicians counsel patients about the incremental risk of major bleeding with extended anticoagulation to guide decision making about treatment duration for unprovoked VTE. Study concept and design: F.K., A.R., M.A.R., D.A.F. Data acquisition: all authors. Statistical analysis: F.K. Drafting of the manuscript: F.K., A.R., M.A.R., D.A.F. Critical revision of the manuscript for important intellectual content: all authors. Final approval of the manuscript: all authors. * Co-senior authors. Received: 13 September 2021 Accepted: 03 November 2021 Accepted Manuscript online: 09 November 2021 Article published online: 29 December 2021 © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyKeywords
Funding Information
- Canadian Institutes of Health Research (CDT-142654)
- Frederick Banting and Charles Best doctoral research scholarship from the Canadian Institutes of Health Research
- Early Postdoc.Mobility Award from the Swiss National Science Foundation (SNSF P2ZHP3_177999)
- Fellowship Award from the CanVECTOR Network
This publication has 36 references indexed in Scilit:
- Apixaban for Extended Treatment of Venous ThromboembolismNew England Journal of Medicine, 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismNew England Journal of Medicine, 2013
- Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trialBMJ, 2007
- d-Dimer Testing to Determine the Duration of Anticoagulation TherapyNew England Journal of Medicine, 2006
- Post‐thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 monthsJournal of Thrombosis and Haemostasis, 2006
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor XimelagatranNew England Journal of Medicine, 2003
- Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous ThromboembolismNew England Journal of Medicine, 2003
- A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous ThromboembolismNew England Journal of Medicine, 1999
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986